BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38692297)

  • 1. CAR T-Cell Therapy in Autoimmune Disease.
    Merkt W; Lorenz HM; Schmitt M
    N Engl J Med; 2024 May; 390(17):1628-1629. PubMed ID: 38692297
    [No Abstract]   [Full Text] [Related]  

  • 2. CAR T-Cell Therapy in Autoimmune Disease.
    Howard JF; Vu T; Mozaffar T
    N Engl J Med; 2024 May; 390(17):1629-1631. PubMed ID: 38692299
    [No Abstract]   [Full Text] [Related]  

  • 3. CAR T-Cell Therapy in Autoimmune Disease.
    De Benedetti F; Diomedi Camassei F; Locatelli F
    N Engl J Med; 2024 May; 390(17):1629. PubMed ID: 38692298
    [No Abstract]   [Full Text] [Related]  

  • 4. CAR T-Cell Therapy in Autoimmune Disease. Reply.
    Müller F; Mackensen A; Schett G
    N Engl J Med; 2024 May; 390(17):1631-1632. PubMed ID: 38692300
    [No Abstract]   [Full Text] [Related]  

  • 5. Chimeric antigen receptor T cell therapy: a new emerging landscape in autoimmune rheumatic diseases.
    Lyu X; Gupta L; Tholouli E; Chinoy H
    Rheumatology (Oxford); 2024 May; 63(5):1206-1216. PubMed ID: 37982747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dawn of CAR-T cell therapy in autoimmune diseases.
    Liu Y; Dong M; Chu Y; Zhou L; You Y; Pang X; Yang S; Zhang L; Chen L; Zhu L; Xiao J; Wang W; Qin C; Tian D
    Chin Med J (Engl); 2024 May; 137(10):1140-1150. PubMed ID: 38613216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T-cell therapy in autoimmune diseases.
    Schett G; Mackensen A; Mougiakakos D
    Lancet; 2023 Nov; 402(10416):2034-2044. PubMed ID: 37748491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is There a Place for Chimeric Antigen Receptor-T Cells in the Treatment of Chronic Autoimmune Rheumatic Diseases?
    Orvain C; Boulch M; Bousso P; Allanore Y; Avouac J
    Arthritis Rheumatol; 2021 Nov; 73(11):1954-1965. PubMed ID: 34042325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T cells for infection, autoimmunity and allotransplantation.
    Maldini CR; Ellis GI; Riley JL
    Nat Rev Immunol; 2018 Oct; 18(10):605-616. PubMed ID: 30046149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for CAR T cell immunotherapy in autoimmune diseases: clues from Lupus.
    Radic M; Neeli I; Marion T
    Expert Opin Biol Ther; 2022 Apr; 22(4):499-507. PubMed ID: 35089116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR-T cell therapy in systemic lupus erythematosus and beyond: a brave new world?
    van Leuven SI; Duivenvoorden R
    Rheumatology (Oxford); 2024 May; 63(5):1192-1194. PubMed ID: 38377390
    [No Abstract]   [Full Text] [Related]  

  • 12. Chimeric antigen receptor T-cell therapy beyond cancer: current practice and future prospects.
    Zhang PF; Xie D; Li Q
    Immunotherapy; 2020 Sep; 12(13):1021-1034. PubMed ID: 32727249
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus.
    Mougiakakos D; Krönke G; Völkl S; Kretschmann S; Aigner M; Kharboutli S; Böltz S; Manger B; Mackensen A; Schett G
    N Engl J Med; 2021 Aug; 385(6):567-569. PubMed ID: 34347960
    [No Abstract]   [Full Text] [Related]  

  • 14. Potential and pitfalls of repurposing the CAR-T cell regimen for the treatment of autoimmune disease.
    Daamen AR; Lipsky PE
    Ann Rheum Dis; 2024 May; 83(6):696-699. PubMed ID: 38637134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma.
    Chow VA; Shadman M; Gopal AK
    Blood; 2018 Aug; 132(8):777-781. PubMed ID: 29914976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus.
    Kansal R; Richardson N; Neeli I; Khawaja S; Chamberlain D; Ghani M; Ghani QU; Balazs L; Beranova-Giorgianni S; Giorgianni F; Kochenderfer JN; Marion T; Albritton LM; Radic M
    Sci Transl Med; 2019 Mar; 11(482):. PubMed ID: 30842314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beyond CD19 CAR-T cells in lymphoma.
    Leung WK; Ayanambakkam A; Heslop HE; Hill LC
    Curr Opin Immunol; 2022 Feb; 74():46-52. PubMed ID: 34800921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
    Schultz L
    Front Immunol; 2020; 11():1985. PubMed ID: 32849662
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safer CAR T-Cell Therapy.
    Abbasi J
    JAMA; 2019 Jun; 321(22):2155. PubMed ID: 31184718
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.